Summation Bio is a gene therapy company that develops a novel non-viral gene transfer technology.
Summation Bio has raised $24.5M in total funding. The most recent round was Series A. The last funding was announced in April 2022.
Summation Bio is headquartered in Somerville, United States.
Summation Bio is a gene therapy company that develops a novel non-viral gene transfer technology.
Summation Bio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Summation Bio — Funding & Investors." VCBacked, April 4, 2022, https://www.vcbacked.co/company/summation-bio. Accessed August 14, 2026.
VCBacked. (2022). Summation Bio — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/summation-bio
{{cite web |title=Summation Bio — Funding & Investors |url=https://www.vcbacked.co/company/summation-bio |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated